Retrovir
Executive Summary
San Diego-based Vical will use its proprietary Prosome technology to develop lipid-modified versions of AZT under a drug development contract with Burroughs Wellcome. The modified drug has demonstrated "the ability to target macrophage cells, which have been shown to be an important factor in the pathogenesis of AIDS," Vical, a two-year old biotech R&D firm, says.